STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

KNSA Form 4: CEO trades via 10b5-1; 111,794 shares direct

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) disclosed insider transactions by its Chairman & CEO under a Rule 10b5-1 plan. On 10/20–10/22/2025, the insider exercised 257,969 share options at $3.80 and sold an equal 257,969 Class A Ordinary Shares in brokered trades.

Weighted average sale prices reported include $38.81 (range $38.14–$39.135), $39.32 (range $39.14–$39.55), $38.77 (range $38.49–$39.235), and $38.83 (range $38.495–$39.255). Following these transactions, direct holdings were 111,794 shares. An additional 109,795 shares were held indirectly by The Marina 2016 Irrevocable Trust.

Positive

  • None.

Negative

  • None.
Insider Patel Sanj K
Role CHAIRMAN & CEO
Sold 257,969 shs ($10.02M)
Approx. gross sale proceeds $10.02M
Approx. exercise cost $980K
Approx. pre-tax spread $9.04M
Type Security Shares Price Value
Exercise Share Option 97,390 $0.00 $0.00
Exercise Class A Ordinary Share 97,390 $3.80 $370K
Sale Class A Ordinary Share 97,390 $38.83 $3.78M
Exercise Share Option 39,331 $0.00 $0.00
Exercise Class A Ordinary Share 39,331 $3.80 $149K
Sale Class A Ordinary Share 39,331 $38.77 $1.52M
Exercise Share Option 121,248 $0.00 $0.00
Exercise Class A Ordinary Share 121,248 $3.80 $461K
Sale Class A Ordinary Share 98,934 $38.81 $3.84M
Sale Class A Ordinary Share 22,314 $39.32 $877K
holding Class A Ordinary Share -- -- --
Holdings After Transaction: Share Option — 0 shares (Direct); Class A Ordinary Share — 111,794 shares (Direct); Class A Ordinary Share — 109,795 shares (Indirect, Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016)
Footnotes (6)
  1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025.
  2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.14 and $39.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  4. F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.49 and $39.235. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  5. F5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.495 and $39.255. The price reported in this column reflects a weighted sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  6. F6. The option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did KNSA’s Chairman & CEO report on Form 4?
Exercised 257,969 options at $3.80 and sold 257,969 Class A shares across 10/20–10/22/2025 under a Rule 10b5-1 plan.

What sale prices were disclosed in the KNSA Form 4?
Weighted averages of $38.81, $39.32, $38.77, and $38.83, with stated price ranges for each trading day.

How many KNSA shares does the insider hold after the transactions?
111,794 shares held directly; 109,795 shares held indirectly by The Marina 2016 Irrevocable Trust.

Were the trades made under a 10b5-1 plan?
Yes. The filing states they were effected pursuant to a 10b5-1 plan executed on May 7, 2025.

What options were exercised and what is their status?
Share options at $3.80 exercise price; the filing states the option is fully vested and exercisable with expiration 06/28/2027.

On which dates did the KNSA insider trade?
Transactions occurred on 10/20/2025, 10/21/2025, and 10/22/2025.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Sanj K
(Last) (First) (Middle)
23 OLD BOND STREET, THIRD FLOOR
(Street)
LONDON X0 W1S 4PZ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHAIRMAN & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Share 10/20/2025 M(1) 121,248 A $3.8 233,042 D
Class A Ordinary Share 10/20/2025 S(1) 98,934 D $38.81(2) 134,108 D
Class A Ordinary Share 10/20/2025 S(1) 22,314 D $39.32(3) 111,794 D
Class A Ordinary Share 10/21/2025 M(1) 39,331 A $3.8 151,125 D
Class A Ordinary Share 10/21/2025 S(1) 39,331 D $38.77(4) 111,794 D
Class A Ordinary Share 10/22/2025 M(1) 97,390 A $3.8 209,184 D
Class A Ordinary Share 10/22/2025 S(1) 97,390 D $38.83(5) 111,794 D
Class A Ordinary Share 109,795 I Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option $3.8 10/20/2025 M(1) 121,248 (6) 06/28/2027 Class A Ordinary Share 121,248 $0 136,721 D
Share Option $3.8 10/21/2025 M(1) 39,331 (6) 06/28/2027 Class A Ordinary Share 39,331 $0 97,390 D
Share Option $3.8 10/22/2025 M(1) 97,390 (6) 06/28/2027 Class A Ordinary Share 97,390 $0 0 D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.14 and $39.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.49 and $39.235. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.495 and $39.255. The price reported in this column reflects a weighted sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
6. The option is fully vested and exercisable.
/s/ Douglas Barry, Attorney-in-Fact 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR